BOSTON– Corsera Health, Inc. today announced its launch with a mission to extend healthspan by predicting and preventing cardiovascular disease, the world’s leading cause of death. Co-founded by RNAi pioneer John Maraganore, Ph.D., and cardiovascular innovator Clive Meanwell, M.D., the company is combining AI-driven risk prediction with preventive RNAi medicines designed for once-annual dosing. Corsera has raised more than $50 million from founders and insiders to date.
The company’s proprietary AI platform, Klotho Health, predicts lifetime risk of atherosclerotic cardiovascular disease (ASCVD) and guides preventive strategies. Corsera is also advancing a dual-targeting RNAi medicine that reduces both PCSK9 and angiotensinogen to lower LDL cholesterol and blood pressure, with first clinical studies planned for the end of 2025.
“Despite treatment advances, cardiovascular disease still claims approximately 21 million lives each year – making this the leading cause of death worldwide,” said Clive Meanwell, M.D., Co-Founder and Co-CEO of Corsera Health. “Today’s care is too little, too late. Our AI-enabled tool identifies people who need earlier intervention to forestall cumulative harm. We expect to disrupt the marketplace by opening new channels to inform, guide, and serve consumers.”
“Through the power of RNAi and our world-class drug discovery efforts, we are swiftly advancing our lead program into the clinic,” said John Maraganore, Ph.D., Co-Founder and Co-CEO of Corsera Health. “We envision a world where a once-annual, dual-targeting preventive RNAi medicine can set a new standard for cardiovascular health and change the trajectory of disease for millions.”
Khurram Nasir, M.D., Chief Medical Advisor at Corsera and Chief of Cardiovascular Prevention & Wellness at Houston Methodist, added: “The NATURE-LEGACY study shows that lifelong exposure to lower LDL cholesterol and blood pressure leads to significant reductions in cardiovascular events. With AI-enabled prediction and a preventive RNAi medicine, Corsera Health is poised to lead the future of cardiovascular prevention.”
Corsera Health was co-founded by Maraganore and Meanwell, longtime collaborators who previously helped advance transformative medicines such as ANGIOMAX and LEQVIO, and who have built companies generating more than $70 billion in shareholder value. Backed by a team with deep scientific, clinical, and business expertise, the company aims to fundamentally reshape cardiovascular care by shifting the focus from treatment to prevention.
